Literature DB >> 20205169

Osteosarcoma.

Richard Gorlick1, Chand Khanna.   

Abstract

It has been difficult to identify the molecular features central to the pathogenesis of osteosarcoma owing to a lack of understanding of the cell or origin, the absence of identifiable precursor lesions, and its marked genetic complexity at the time of presentation. Interestingly, several human genetic disorders and familial cancer syndromes, such as Li-Fraumeni syndrome, are linked to an increased risk of osteosarcoma. Association of these same genetic alterations and osteosarcoma risk have been confirmed in murine models. Osteosarcoma is associated with a variety of genetic abnormalities that are among the most commonly observed in human cancer; it remains unclear, however, what events initiate and are necessary to form osteosarcoma. The availability of new resources for studying osteosarcoma and newer research methodologies offer an opportunity and promise to answer these currently unanswered questions. Even in the absence of a more fundamental understanding of osteosarcoma, association studies and preclinical drug testing may yield clinically relevant information. Copyright 2010 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Year:  2010        PMID: 20205169     DOI: 10.1002/jbmr.77

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  59 in total

1.  CANCER STEM CELLS IN OSTEOSARCOMA.

Authors:  Lindsay Bashur; Guang Zhou
Journal:  Case Orthop J       Date:  2013

2.  Expression of Phosphoinositide-specific phospholipase C enzymes in human osteosarcoma cell lines.

Authors:  Vincenza Rita Lo Vasco; Martina Leopizzi; Caterina Chiappetta; Chiara Puggioni; Claudio Di Cristofano; Carlo Della Rocca
Journal:  J Cell Commun Signal       Date:  2013-02-22       Impact factor: 5.782

3.  Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma.

Authors:  Sara Del Mare; Kyle C Kurek; Gary S Stein; Jane B Lian; Rami I Aqeilan
Journal:  Am J Cancer Res       Date:  2011-04-03       Impact factor: 6.166

4.  Bone morphogenetic protein 9 overexpression reduces osteosarcoma cell migration and invasion.

Authors:  Zilan Lv; Dandan Yang; Jie Li; Min Hu; Min Luo; Xiaoqin Zhan; Peipei Song; Chen Liu; Huili Bai; Baolin Li; Yang Yang; Yingying Chen; Qiong Shi; Yaguang Weng
Journal:  Mol Cells       Date:  2013-06-25       Impact factor: 5.034

5.  Expression and clinical significance of cyclooxygenase-2 and microRNA-143 in osteosarcoma.

Authors:  Yongchao Fang; Zhiqiang Zhang; Qiang Wang; Jianning Zhao
Journal:  Exp Ther Med       Date:  2015-04-14       Impact factor: 2.447

6.  β-Catenin transcriptional activity is minimal in canine osteosarcoma and its targeted inhibition results in minimal changes to cell line behaviour.

Authors:  Caroline M Piskun; Timothy J Stein
Journal:  Vet Comp Oncol       Date:  2013-11-21       Impact factor: 2.613

Review 7.  Molecular genetics of osteosarcoma.

Authors:  Kirby Rickel; Fang Fang; Jianning Tao
Journal:  Bone       Date:  2016-10-17       Impact factor: 4.398

8.  MicroRNA-2682-3p inhibits osteosarcoma cell proliferation by targeting CCND2, MMP8 and Myd88.

Authors:  Fan Zhang; Yanjie Zhu; Guoxin Fan; Shuo Hu
Journal:  Oncol Lett       Date:  2018-06-27       Impact factor: 2.967

9.  In vitro and in vivo antitumor effects of the VO-chrysin complex on a new three-dimensional osteosarcoma spheroids model and a xenograft tumor in mice.

Authors:  Ignacio E León; Juan F Cadavid-Vargas; Agustina Resasco; Fabricio Maschi; Miguel A Ayala; Cecilia Carbone; Susana B Etcheverry
Journal:  J Biol Inorg Chem       Date:  2016-10-01       Impact factor: 3.358

10.  THE COP9 SIGNALOSOME, A NOVEL, ESSENTIAL REGULATOR OF SKELETAL DEVELOPMENT AND TUMORIGENESIS.

Authors:  Lindsay Bashur; Dongxing Chen; Guang Zhou
Journal:  Case Orthop J       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.